Natural killer cells for advanced neuroblastoma
Part of Cancer clinical trials.
This trial tests a new type of immune cell called natural killer (NK) cells from healthy donors to treat neuroblastoma that has not responded to standard treatments. The goal is to see if these cells can help shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have high-risk neuroblastoma that didn't get better with standard chemotherapy (at least 4 cycles).
- Your cancer has come back or kept growing after a stem cell transplant or other strong treatment.
- You have a tumor that can be measured on a CT or MRI scan and shows up on a special MIBG or PET scan.
- Your blood counts (platelets, white blood cells, red blood cells) are in a safe range without needing transfusions.
- Your liver, kidneys, heart, and lungs are working well enough to handle the new treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immune cell therapy (called CNK-UT) for children whose neuroblastoma has come back or hasn't responded to standard treatments. The goal is to see if these cells can find and attack the cancer. Participation may be an option if your child's tumor has a specific marker (B7-H3) and their overall health is stable enough.
This trial tests a combination of chemotherapy, immunotherapy, and natural killer (NK) cell therapy for children with high-risk neuroblastoma or ganglioneuroblastoma that has not responded to initial treatment or has come back after treatment. The goal is to see if this approach can help destroy cancer cells more effectively.
This trial tests a new treatment using donated natural killer (NK) cells injected into the body to fight high-grade brain tumors. It might help people with certain types of aggressive gliomas that are newly diagnosed.
This trial tests specially prepared immune cells (called CIML-NK cells) from a partially matched family donor to fight neuroblastoma that has returned or stopped responding to standard treatment. The goal is to see if these cells can help patients whose cancer is difficult to control.
This trial tests a new natural killer (NK) cell therapy from donated umbilical cord blood for children with high-risk neuroblastoma that has come back or not responded to treatment. The goal is to see if this immune cell therapy is safe and can help fight the cancer.
This early-phase study tests whether giving donated NK cells with three medicines can shrink neuroblastoma that has come back or not responded well to prior treatment. It’s designed for people who have limited options, and the goal is to see safety and whether the combination works.
Hear when a new Neuroblastoma (NB) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.